Article Cited by others


Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells

Premkumar Daniel R, Jane Esther P, Agostino Naomi R, Scialabba Joseph L, Pollack Ian F

Year : 2010| Volume: 9| Issue : 1 | Page no: 7-7

   This article has been cited by
1 Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention
Ailian Xiong,Zhengduo Yang,Yicheng Shen,Jia Zhou,Qiang Shen
Cancers. 2014; 6(2): 926
[Pubmed]  [Google Scholar] [DOI]
2 Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells
McFarland, B.C. and Gray, G.K. and Nozell, S.E. and Hong, S.W. and Benveniste, E.N.
Molecular Cancer Research. 2013; 11(5): 494-505
[Pubmed]  [Google Scholar]
3 In Vitro Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma
Veringa, S.J.E. and Biesmans, D. and van Vuurden, D.G. and Jansen, M.H.A. and Wedekind, L.E. and Horsman, I. and Wesseling, P. and Vandertop, W.P. and Noske, D.P. and Kaspers, G.J.J.L. and Hulleman, E.
PLoS ONE. 2013; 8(4)
[Pubmed]  [Google Scholar]
4 STAT signaling in glioma cells
Swiatek-Machado, K. and Kaminska, B.
Advances in Experimental Medicine and Biology. 2013; 986: 189-208
[Pubmed]  [Google Scholar]
5 Kinase regulation by sulfur and selenium containing compounds
Sanmartín, C., Plano, D., Font, M., Palop, J.A.
Current Cancer Drug Targets. 2011; 11(4): 496-523
[Pubmed]  [Google Scholar]
6 Signal transducer and activator of transcription 3 (STAT3): A promising target for anticancer therapy
Masciocchi, D., Gelain, A., Villa, S., Meneghetti, F., Barlocco, D.
Future Medicinal Chemistry. 2011; 3(5): 567-597
[Pubmed]  [Google Scholar]
7 Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain
Sagar Agarwal,Ramola Sane,Rajneet Oberoi,John R. Ohlfest,William F. Elmquist
Expert Reviews in Molecular Medicine. 2011; 13
[Pubmed]  [Google Scholar] [DOI]
8 Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors
Montero, J.C., Seoane, S., Ocaña, A., Pandiella, A.
Clinical Cancer Research. 2011; 17(17): 5546-5552
[Pubmed]  [Google Scholar]


Read this article